CYTH Cyclo Therapeutics
- 1.260
- -0.030-2.33%
Cyclo Therapeutics News
Cyclo Therapeutics Initiated at Buy by Ascendiant Capital
Cyclo Therapeutics Initiated at Buy by Ascendiant Capital
Cyclo Therapeutics (CYTH.US) was first covered by Ascendiant Capital, giving it a buy rating, with a target price of $2.60.
Cyclo Therapeutics (CYTH.US) was first covered by Ascendiant Capital, giving it a buy rating, with a target price of $2.60.
Ascendiant Capital Initiates Coverage On Cyclo Therapeutics With Buy Rating, Announces Price Target of $2.6
Ascendiant Capital analyst Lucas Ward initiates coverage on Cyclo Therapeutics (NASDAQ:CYTH) with a Buy rating and announces Price Target of $2.6.
Cyclo Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 124.14% Ascendiant Capital → $2.6 Initiates Coverage On → Buy 09/27/2023 244.83% Maxim Group →
Analysts Offer Insights on Healthcare Companies: Cyclo Therapeutics (CYTH), CytomX Therapeutics (CTMX) and Pacific Biosciences (PACB)
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. Biora Therapeutics (NASDAQ:BIOR) share
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersOneMedNet (NASDAQ:ONMD) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. The market value of their outstanding shares is at $44.8 million. Aesthetic Medical Intl (N
Cyclo Therapeutics Receives Decision To Grant European Patent Titled 'METHODS FOR TREATING ALZHEIMER'S DISEASE WITH HP-[BETA]-CYCLODEXTRIN'
Cyclo Therapeutics Receives Decision To Grant European Patent Titled 'METHODS FOR TREATING ALZHEIMER'S DISEASE WITH HP-[BETA]-CYCLODEXTRIN'
Buy Rating Affirmed for Cyclo Therapeutics on Strong Clinical and Financial Prospects
Cyclo Therapeutics FY23 EPS $(1.23) Up From $(1.83) YoY; Revenue $1.076M Down From $1.375M YoY
Cyclo Therapeutics FY23 EPS $(1.23) Up From $(1.83) YoY; Revenue $1.076M Down From $1.375M YoY
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Ended the year with approximately $9.2 million cash to fund operations; continued efforts to bolster cash position and extend runway through clinical and regulatory milestones.
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol Cyclo for the Treatment of Alzheimer's Disease
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medici
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease From the U.S. Patent and Trademark Office
Cyclo Therapeutics Regains Compliance With Nasdaq Standards
12 Health Care Stocks Moving In Monday's Intraday Session
GainersAtreca (NASDAQ:BCEL) stock rose 52.7% to $0.36 during Monday's regular session. The market value of their outstanding shares is at $14.1 million. Cyclo Therapeutics (NASDAQ:CYTH) shares rose 29
News On Applied Molecular Transport Inc. (AMTI) Now Under CYTH
News On Applied Molecular Transport Inc. (AMTI) Now Under CYTH
Cytosorbents, Cyclo Therapeutics Among Healthcare Movers
Marathon Digital, Hut 8, AEye Among Premarket Losers' Pack
Analysis
Price Target
No Data
